3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 2
1
Status
Completed
2
Recruiting
1
Sponsor Class
OTHER
2
OTHER_GOV
1
Study Type
Interventional
3
Sponsor
Cancer Type
Other hematologic neoplasm
3
Conditions
Neoplasms
5
Hemorrhage
5
Hematologic Neoplasms
3
Head and Neck Neoplasms
2
Brain Neoplasms
2
Bone Neoplasms
2
Recurrence
1
Prostatic Neoplasms
1
Postoperative Complications
1
Osteosarcoma
1
Myofibroma
1
Metrorrhagia
1
Meningioma
1
Melanoma
1
Leiomyoma
1
Glioma
1
Breast Neoplasms
1
Astrocytoma
1
Interventions
Olanzapine
4
Cyclophosphamide
4
Voriconazole
3
Tranexamic Acid
3
Standard of Care
3
nilotinib
2
letermovir
2
fludarabine phosphate
2
Zoledronic Acid
2
Whole-Body Irradiation
2
Practice Guidelines as Topic
2
Peripheral Blood Stem Cell Transplantation
2
Mycophenolic Acid
2
Methods
2
Imatinib Mesylate
2
Educational Status
2
Early Intervention, Educational
2
Doxorubicin
2
Cyclosporins
2
Cyclosporine
2
venetoclax
1
trihexyltetradecylphosphonium chloride
1
thymoglobulin
1
shengxuening
1
posaconazole
1
pembrolizumab
1
olaparib
1
maribavir
1
lenvatinib
1
ferrous succinate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
Hematologic Neoplasms
×
Tranexamic Acid
×
Clear all
NCT04448184
2026-01-08
PATH
Ottawa Hospital Research Institute
Phase 3
Recruiting
662 enrolled
NCT03136445
2025-10-28
TREATT
NHS Blood and Transplant
Phase 3
Completed
616 enrolled
34 charts
NCT02650791
2020-05-18
PATH
Ottawa Hospital Research Institute
Phase 3
Completed
100 enrolled